Identity
HGNC
LOCATION
Xq24
LOCUSID
ALIAS
2F1,AAC2,ANT2,T2,T3
FUSION GENES
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 292
MIM: 300150
HGNC: 10991
Ensembl: ENSG00000005022
Variants:
dbSNP: 292
ClinVar: 292
TCGA: ENSG00000005022
COSMIC: SLC25A5
RNA/Proteins
| Gene ID | Transcript ID | Uniprot |
|---|---|---|
| ENSG00000005022 | ENST00000317881 | P05141 |
Expression (GTEx)
Pathways
Protein levels (Protein atlas)
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 34676827 | 2021 | ANT2 drives proinflammatory macrophage activation in obesity. | 5 |
| 34676827 | 2021 | ANT2 drives proinflammatory macrophage activation in obesity. | 5 |
| 33396658 | 2020 | Differential Expression of ADP/ATP Carriers as a Biomarker of Metabolic Remodeling and Survival in Kidney Cancers. | 7 |
| 33396658 | 2020 | Differential Expression of ADP/ATP Carriers as a Biomarker of Metabolic Remodeling and Survival in Kidney Cancers. | 7 |
| 30225759 | 2019 | Adenine Nucleotide Translocase 2 as an Enzyme Related to [(18)F] FDG Accumulation in Various Cancers. | 5 |
| 30225759 | 2019 | Adenine Nucleotide Translocase 2 as an Enzyme Related to [(18)F] FDG Accumulation in Various Cancers. | 5 |
| 28350139 | 2017 | Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. | 27 |
| 28350139 | 2017 | Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma. | 27 |
| 25982278 | 2016 | IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. | 45 |
| 26842067 | 2016 | Changes in the expression of the human adenine nucleotide translocase isoforms condition cellular metabolic/proliferative status. | 4 |
| 26883272 | 2016 | Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. | 0 |
| 27012708 | 2016 | ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells. | 22 |
| 25982278 | 2016 | IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2. | 45 |
| 26842067 | 2016 | Changes in the expression of the human adenine nucleotide translocase isoforms condition cellular metabolic/proliferative status. | 4 |
| 26883272 | 2016 | Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. | 0 |
Citation
Dessen P
SLC25A5 (solute carrier family 25 member 5)
Atlas Genet Cytogenet Oncol Haematol. 2007-02-01
Online version: http://atlasgeneticsoncology.org/gene/46455/slc25a5
